Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Surveillance vs. Anticoagulation for Low-risk Isolated Subsegmental Pulmonary Embolism
2023-507801-32-00Phase 4Authorised
- Sponsor
- Insel Gruppe
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in pulmonary embolism (PE) comparing Rivaroxaban anticoagulation with Clinical surveillance with placebo (2 arms). Primary endpoint: Recurrent venous thromboembolism at 90 days. Planned start Oct 2023; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2023-507801-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507801-32-00.